普昂医疗（920069）：北交所新股申购报告：输注穿刺器械小巨人全球市占率 Top3，胰岛素笔针+微创介入双轮驱动

Investment Rating - The report does not explicitly state an investment rating for the company [1] Core Insights - The company, Puan Medical, is recognized as a national-level specialized and innovative "little giant," focusing on diabetes care, general drug infusion, and minimally invasive interventional medical devices [1][13] - The core product is the insulin pen needle, which accounted for 65.80% of revenue in the first half of 2025, with total revenue projected to reach 318 million yuan in 2024, a year-on-year increase of 34.61% [1][18] - The company has a strong growth trajectory, with a net profit of 64.88 million yuan in 2024, reflecting a 41.34% year-on-year increase [1][10] - The gross margin and net margin for 2024 are expected to be 49.44% and 20.38%, respectively [1][10] Company Overview - Puan Medical's revenue from diabetes care products is projected to be 263 million yuan in 2024, with a year-on-year growth of 29.62% [1][28] - The company has a significant market share in the insulin pen needle segment, with a global market share of 11.78% in 2024, ranking second globally [3][11] - The company has established a strong customer base, with over 70 clients across various countries, including partnerships with well-known brands [3][11] Industry Insights - The global medical device market is projected to grow from 566.2 billion USD in 2023 to 772.5 billion USD by 2029 [2] - The Chinese medical infusion and puncture device market is expected to reach 52.3 billion yuan by 2026, with the diabetes care segment showing significant growth potential [2][3] - The global insulin pen needle market is projected to reach 1.35 billion USD in 2024, with a compound annual growth rate (CAGR) of 5.8% [2][3] Financial Performance - The company achieved a revenue of 3.18 billion yuan in 2024, with a gross margin of 49.44% and a net margin of 20.38% [1][10] - The revenue from general drug infusion products is expected to be 40.75 million yuan in 2024, reflecting a year-on-year growth of 47.41% [1][42] - The revenue from minimally invasive interventional products is projected to grow significantly, with a year-on-year increase of 272% in 2024 [1][11]